Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing
暂无分享,去创建一个
[1] P. Brennan,et al. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control , 2016, Oncotarget.
[2] S. Knuutila,et al. Hot spot mutations in Finnish non-small cell lung cancers. , 2016, Lung cancer.
[3] P. Piirilä,et al. Exhaled breath condensate as a source of biomarkers for lung carcinomas. A focus on genetic and epigenetic markers—A mini‐review , 2016, Genes, chromosomes & cancer.
[4] M. Olivier,et al. Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer , 2016, EBioMedicine.
[5] Scott R. Kennedy,et al. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues , 2016, Proceedings of the National Academy of Sciences.
[6] Jimin Liang,et al. Cell-free circulating tumor DNA in cancer , 2016, Chinese journal of cancer.
[7] H. Guadalajara,et al. KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients , 2016, International journal of molecular sciences.
[8] S. Knuutila,et al. Genetic alterations in periprosthetic soft-tissue masses from patients with metal-on-metal hip replacement. , 2015, Mutation research.
[9] M. Tsao,et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. , 2015, Translational lung cancer research.
[10] J. T. Dunnen,et al. Next generation sequencing technology: Advances and applications. , 2014, Biochimica et biophysica acta.
[11] Heng Zhao,et al. Identification of candidate genes for lung cancer somatic mutation test kits , 2013, Genetics and molecular biology.
[12] J. Andrews,et al. Comparison of Targeted Next‐Generation Sequencing (NGS) and Real‐Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin‐Fixed, Paraffin‐Embedded Tumor Material of Non‐Small Cell Lung Carcinoma—Superiority of NGS , 2013, Genes, chromosomes & cancer.
[13] J. Szemraj,et al. Complete surgical resection of lung tumor decreases exhalation of mutated KRAS oncogene. , 2012, Respiratory medicine.
[14] Richard W Tothill,et al. Next-generation sequencing for cancer diagnostics: a practical perspective. , 2011, The Clinical biochemist. Reviews.
[15] M. Albitar,et al. Somatic mutations of signaling genes in non-small-cell lung cancer. , 2010, Cancer genetics and cytogenetics.
[16] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[17] F. Clavel-Chapelon,et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. , 2006, Cancer research.
[18] F. Clavel-Chapelon,et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. , 2006, Carcinogenesis.
[19] T. Sun,et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation , 2001, Oncogene.
[20] F. A. Benko,et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. , 2000, Journal of the National Cancer Institute.
[21] Z. Ronai,et al. High frequency of K‐ras mutations in normal appearing lung tissues and sputum of patients with lung cancer , 1995, International journal of cancer.
[22] F. Boccardo,et al. Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. , 2015, Current drug targets.
[23] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[24] Z. Ronai,et al. K‐ras mutation in sputum of patients with or without lung cancer , 1996, Journal of cellular biochemistry. Supplement.